Acthar Gel for Active Systemic Lupus Erythematosus (SLE)
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids
Sponsor: Mallinckrodt
This PHASE4 trial investigates Lupus Erythematosus, Systemic and is currently completed. Mallinckrodt leads this study, which shows 16 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
16 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 11 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Dec 2019 — Sep 2020 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Nov 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE4
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2018 — Apr 2018 [monthly]
Recruiting PHASE4
-
Aug 2017 — Jan 2018 [monthly]
Recruiting PHASE4
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mallinckrodt
For direct contact, visit the study record on ClinicalTrials.gov .